ResearcherUniversité Libre de BruxellesActive in the last 2 years
Alain Hendlisz
Matched on ORCID iD 0000-0003-2122-1948; OpenAlex author ID A5060058983. Sources: ClinicalTrials.gov.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 54
2012: 1 paper · 2013: 1 trial · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 8
- Pain management in pancreatic cancer: time to change our strategy! First author DOI 10.1097/cco.0000000000001251↗
- Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.3390/diagnostics14070712↗
- Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Co-author DOI 10.1016/j.esmoop.2021.100356↗
- Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Co-author DOI 10.1177/17588359211045860↗
- Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Co-author DOI 10.1177/1758835920936093↗
- [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma]. Co-author PMID 26502580↗
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
- New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
Trials 1
Closest collaborators
The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel Bléro · 1 shared paper, 2026 · strength 0.63
- Jean‐Luc Van Laethem · 4 shared papers, 2012–2024 · strength 0.47
- Paper Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multi… DOI 10.3390/diagnostics14070712↗
- Paper Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? DOI 10.1177/1758835920936093↗
- Paper Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatme… DOI 10.1177/17588359211045860↗
- Maria Antonietta Bali · 2 shared papers, 2021–2024 · strength 0.32
- Paper Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multi… DOI 10.3390/diagnostics14070712↗
- Paper Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatme… DOI 10.1177/17588359211045860↗
- Julie Navez · 2 shared papers, 2020–2021 · strength 0.24
- Jean Closset · 2 shared papers, 2020–2021 · strength 0.24
- Christelle Bouchart · 2 shared papers, 2020–2021 · strength 0.24
- Ayoub Mokhtari · 1 shared paper, 2024 · strength 0.21
- Nam Quoc Nguyen · 1 shared paper, 2022 · strength 0.13
- Paul J. Ross · 1 shared paper, 2022 · strength 0.13
- Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13
- Marion Harris · 1 shared paper, 2022 · strength 0.13
- Mehrdad Nikfarjam · 1 shared paper, 2022 · strength 0.13
- Daniel Gerald Croagh · 1 shared paper, 2022 · strength 0.13
- Thankamma Ajithkumar · 1 shared paper, 2022 · strength 0.13
- Harpreet Singh Wasan · 1 shared paper, 2022 · strength 0.13
- Matthieu Hein · 1 shared paper, 2021 · strength 0.11
- Raphaël Maréchal · 2 shared papers, 2012–2015 · strength 0.07
- Emmanuel Mitry · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Thierry Conroy · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Geertjan van Tienhoven · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Manfred Paul Lutz · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- John P. Neoptolemos · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Michel Pierre Ducreux · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Pascal R. Hammel · 2 shared papers, 2012–2014 · strength 0.05
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Daniel Van Daele · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.